Recital 15, Regulation (EU) 2024/3169

In forcesince 18 Dec 2024

Where joint scientific consultations on medicinal products are conducted in parallel with the scientific advice, the HTA secretariat and the European Medicines Agency should exchange the respective lists of issues. The JSC Subgroup and the European Medicines Agency should discuss the lists of issues with the health technology developer in one single meeting. It should be specified which parties are to be invited to this joint meeting. The meeting should be held virtually and be co-chaired by the assessor or co-assessor for joint scientific consultation appointed pursuant to Article 18(3) of Regulation (EU) 2021/2282 (‘the assessor and co-assessor’) and one of the coordinators for scientific advice.